Abstract 251P
Background
According to data of Globocan 2018 year, 18.1 million of new cancer cases have been registered and more than half of these cases occur in the Asian continent. Moreover, among women, cervical cancer takes the 4th place in morbidity and mortality. In the Republic of Uzbekistan cervical cancer takes third place among all cancers. Thus, remaining one of the frequent oncogynecological pathology, cervical cancer is a serious public health problem both in the world and in Uzbekistan.
Methods
To analyze condition of morbidity and mortality of cervical cancer we studied the state report -Information on diseases of malignant neoplasms.
Results
The average age of patients with cervical cancer was 61.3 in 2009 y, and 58.3 in 2019y. In 2009 y, the incidence rate per 100,000 population was 4.6, and in 2019 y this indicator increased to 5.6. Moreover, the highest incidence rate per 100,000 population in 2009 was observed in the Republic of Karakalpakstan, Tashkent city, Namangan, Andijan and Khorezm regions with indicators of 7.3; 7.0; 6.3; 5.8 and 5.7 per 100,000 population respectively, and the lowest in Surkhandarya (2.2), Kashkadarya (2.8) and Jizzakh (3.2) regions. In comparison of 2019 y, the highest incidence rate per 100,000 population was in Tashkent, the Republic of Karakalpakstan, Namangan and Khorezm regions with indicators of 11.8; 7.3; 6.8 and 6.5, respectively, and the lowest was observed in Kashkadarya (4.3), Samarkand (3.7) and Surkhandarya (2.8) regions. According to mortality rates, it was showed that there was growth of this indicator from 2.0 per 100,000 population in 2009 y to 3.0 per 100,000 population in 2019 y. Relatively high mortality rate per 100,000 population in 2009 y was observed in Tashkent (4.2), Khorezm (3.4) and Tashkent (2.9) regions, and in 2019 in the Republic of Karakalpakistan, Namangan and Khorezm regions with indicators of 5.8; 5.1 and 4.8, respectively.
Conclusions
In conclusion it can be shown that cervical cancer has a tendency to increase both morbidity and mortality in the Republic of Uzbekistan. The increase in morbidity is due to the intensive work of primary medical care, implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards, and screening programs.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session